RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach
Bera, TK., Maitra, R., Iavarone, C., Salvatore, G., Kumar, V., Vincent, JJ., Sathyanarayana, BK., Durray, P., Lee, BK., & Pastan, I. (2002). PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach. Proceedings of the National Academy of Sciences of the United States of America, 99(5), 3058-3063. http://www.pnas.org/content/99/5/3058.abstract
To identify target antigens for prostate cancer therapy, we have combined computer-based screening of the human expressed sequence tag database and experimental expression analysis to identify genes that are expressed in normal prostate and prostate cancer but not in essential human tissues. Using this approach, we identified a gene that is expressed specifically in prostate cancer, normal prostate, and testis. The gene has a 1.5-kb transcript that encodes a protein of 14 kDa. We named this gene PATE (expressed in prostate and testis). In situ hybridization shows that PATE mRNA is expressed in the epithelial cells of prostate cancers and in normal prostate. Transfection of the PATE cDNA with a Myc epitope tag into NIH 3T3 cells and subsequent cell fractionation analysis shows that the PATE protein is localized in the membrane fraction of the cell. Analysis of the amino acid sequence of PATE shows that it has structural similarities to a group of proteins known as three-finger toxins, which includes the extracellular domain of the type ? transforming growth factor receptor. Restricted expression of PATE makes it a potential candidate for the immunotherapy of prostate cancer.